Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance

Not Applicable

Completed

• Conditions: polycystic ovary syndrome; hyperlipidemia and impaired glucose tolerance; Metabolic and Endocrine - Metabolic disorders; Blood - Other blood disorders

• Registration Number: ACTRN12611000886987
• Lead Sponsor: Ozlem Celik

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-08-19
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 40

Inclusion Criteria

PCOS was defined according to Rotterdam European Society for Human Reproduction and Embryology (ESHRE) and the American Society for Reproductive Medicine(ASRM) consensus workshop. All patients had at least two of the following three criteria: chronic anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovaries on ultrasound (USG).

Exclusion Criteria

The patients who had liver and kidney diseases and using drugs affecting insulin sensitivity and lipid profile and oral contraceptives within the last six months were excluded from the study. Patients with Cushing's syndrome, hyperprolactinemia, diabetes mellitus, thyroid disease, congenital adrenal hyperplasia and androgen-secreting tumors, insufficient LH syndrome and other endocrinopathies were also excluded from the study.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Total and free testosterone, insulin, glucose and hs-CRP levels. Blood samples were obtained before and after treatment. They assesed with biochemical tests.[before treatment and after 12 weeks of treatment]

Secondary Outcome Measures

Name	Time	Method
il[Nil]